Yingpei Zhang,Jiajun Wang,Yibin Tan et al.
Yingpei Zhang et al.
High-dose tigecycline is gradually being introduced for the treatment of serious infectious diseases due to the increasing difficulty in treating pan-resistant bacterial infections. However, the safety of high-dose tigecycline is controvers...
Calcineurin inhibitors in unplanned pregnancies with active lupus disease: A retrospective observational study [0.03%]
一项回顾性观察研究：意外怀孕伴系统性红斑狼疮活动期患者使用钙调磷酸酶抑制剂的情况
İbrahim Vasi,Derya Yıldırım,Rıza Can Kardaş et al.
İbrahim Vasi et al.
Objectives: To evaluate the use of calcineurin inhibitors (CNIs), specifically tacrolimus, in unplanned pregnancies with active lupus disease among patients with systemic lupus erythematosus (SLE). ...
Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis [0.03%]
山莨菪碱治疗流涎的系统评价和meta分析
Venkata K Yellepeddi,Jonathan A Race,Mary M McFarland et al.
Venkata K Yellepeddi et al.
Objectives: To describe the efficacy of atropine in controlling salivary flow in patients with sialorrhea or drooling. Materials and methods: ...
Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen [0.03%]
Privigen治疗慢性淋巴细胞白血病合并继发性免疫缺陷患者中血清IgG浓度与感染发生率的关系研究
Burkhard Otremba,Ferdinand Haslbauer,Marcel Reiser et al.
Burkhard Otremba et al.
Objective: To investigate the association between serum immunoglobulin G (IgG) concentrations and the incidence of infections in patients with chronic lymphocytic leukemia (CLL) and secondary immunodeficiency receiving tr...
A crossover study to evaluate the pharmacokinetics and bioequivalence of hydroxychloroquine tablets in healthy Chinese subjects [0.03%]
评价羟氯喹片在健康受试者中药代动力学和生物等效性的交叉试验
Jie Feng,Shuang-Yu Kuang,Jun-Han Wan et al.
Jie Feng et al.
Aims: Hydroxychloroquine (HCQ) has a high variability and a long half-life in the human body. The purpose of this study was to evaluate the bioequivalence of a generic HCQ tablet (test preparation) versus a brand HCQ tabl...
Randomized Controlled Trial
International journal of clinical pharmacology and therapeutics. 2024 Jun;62(6):284-292. DOI:10.5414/CP204406 2024
Therapeutic drug monitoring of vancomycin in surgical patients using a validated HPLC method [0.03%]
外科患者万古霉素治疗药物监测中验证过的HPLC方法的应用
Muhammad Noman Akram,Muhammad Imran Khokhar,Mateen Abbas et al.
Muhammad Noman Akram et al.
Background: Vancomycin is being used for the treatment of a variety of infections caused by methicillin resistant Staphylococcus aureus and methicillin susceptible Staphylococcus aureus. Therapeutic drug monitoring (TDM) ...
Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials [0.03%]
阿利珠单抗和依洛珠单抗用于卒中及心血管事件的一级和二级预防的Meta分析：随机试验的事后分析
Kwang-Hee Shin,Hye Duck Choi
Kwang-Hee Shin
Objectives: Although the clinical role of protein convertase subtilisin kexin type 9 (PCSK9) inhibitors for cholesterol management is increasing, the post-marketing period of use is short compared to other lipid-lowering ...
Efficacy and safety of antiplatelet therapy in COVID-19: Insights from a meta-analysis of randomized controlled trials [0.03%]
抗血小板治疗在COVID-19中的疗效和安全性：随机对照试验的荟萃分析的见解
Guoying Kao,Yunlin Chen,Jinqi Fan
Guoying Kao
Background: COVID-19 induces a pro-coagulant state with thrombotic events. This meta-analysis explores the efficacy and safety of antiplatelet-based therapy in COVID-19 patients through randomized controlled trials (RCTs)...
Low albumin combined with low-molecular-weight heparin as risk factors for liver injury using azvudine: Evidence from an analysis of COVID-19 patients in a national prospective pharmacovigilance database [0.03%]
低白蛋白血症联合低分子肝素作为使用阿扎那韦引起肝脏损伤的风险因素：来自全国前瞻性药物警戒数据库的COVID-19患者的分析证据
Hong Lu,Ying Zeng,Qun-Zhi Shi et al.
Hong Lu et al.
Objective: Azvudine is an effective treatment for patients infected with common COVID-19. However, physicians have reported a series of adverse reactions, including multiple cases of liver injury, caused by azvudine in cl...
Evaluation of the risk factors for the failure of a single prophylactic dose of anticholinergic drugs for irinotecan-induced cholinergic symptoms [0.03%]
评估单次预防性抗胆碱能药物治疗伊立替康引起的胆碱能症状失败的风险因素
Takuya Watanabe,Yoshitaka Saito,Yoh Takekuma et al.
Takuya Watanabe et al.
Objective: Irinotecan (IRI) is an anticancer drug that is frequently used to treat colorectal, gastric, and pancreatic cancers. Its side effects include cholinergic symptoms, such as diarrhea, abdominal pain, nausea, and ...